Previous 10 | Next 10 |
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi ® is indicated in...
- Priority Review acceptance based on positive results of AGAVE-201 study Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the tre...
2024-02-23 11:14:07 ET More on Incyte Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab JMP cuts Incyte...
2024-02-18 06:39:11 ET Summary This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February. ... ...
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
2024-02-14 15:20:31 ET More on Incyte Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte Q4 2023 ...
2024-02-14 09:15:02 ET Truist Financial analyst issues MARKET OUTPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Market Outperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall ana...
2024-02-14 09:15:02 ET Mizuho Securities analyst issues UNDERPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Underperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall analyst cons...
2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...
2024-02-13 12:37:03 ET Incyte Corporation (INCY) Q4 2023 Earnings Conference Call February 13, 2024, 08:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Hervé Hoppenot - Chief Executive Officer Barry Flannelly - General...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...